Is Beaten-Down Dexcom Stock a Buy on the Dip?

The market may have overreacted to a disappointing earnings report.Last week was a tough one for Dexcom (DXCM -40.66%) shareholders. The maker of continuous blood glucose monitors lowered its forward revenue outlook when it reported second-quarter results on Friday, July 26.If there's one thing markets hate, it's uncertainty. Investors responding to management's shifting expectations hammered the stock 40.6% lower in a single trading session. That beat the stock down to a price we haven't seen since early 2 ...